19
Participants
Start Date
July 1, 2021
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2026
Orelabrutinib
Orelabrutinib: 150 mg orally once daily
Sintilimab
Sintilimab: 200 mg intravenously every 3 weeks
Temozolomide (TMZ)
Temozolomide: 150 mg/m² orally on days 1-5 of each 21-day cycle
RECRUITING
2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou
Sir Run Run Shaw Hospital
OTHER
First Affiliated Hospital of Zhejiang University
OTHER
Wenzhou Central Hospital
OTHER
Second Affiliated Hospital of Wenzhou Medical University
OTHER
Zhejiang Provincial Tongde Hospital
OTHER
First People's Hospital of Hangzhou
OTHER
Zhejiang Provincial People's Hospital
OTHER
Jinhua Central Hospital
OTHER
Jinhua People's Hospital
OTHER
Yinzhou Hospital Affiliated to Medical School of Ningbo University
OTHER
Huzhou Central Hospital
OTHER
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER